ClinicalTrials.gg
RecruitingNCT06193850Updated Jan 5, 2024

Protocol N. 2014 - Observational Study on the Quality of Life of Outpatients

An observational study in Urologic Diseases, Male Infertility and Sexual Medicine, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2015; still recruiting 11 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Urologic Diseases with a site in Italy — 4 open to participants now, 7 under way, 3 of them phase 3. Urologic Diseases · Italy.

Started
2015
with 2 others
Observational
4 of 22
3 open now
Registered
20th of 22
by date
Lead sponsor
2 of 22
IRCCS San Raffaele

Among the 22 studies in Urologic Diseases with a site in Italy, this one is one of 3 that started in 2015, is one of 4 observational ones, and was the 20th registered.

Urologic Diseases

221 studies on the registry are indexed under Urologic Diseases; 48 are open to participants now.

Browse Urologic Diseases studies →

Open to participants now

4 of the 22 studies in Urologic Diseases with a site in Italy are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 37 Urologic Diseases studies recruiting now, 24 (65%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Urologic Diseases with a site in Italy, or all of them as a file.
02

Study summary

Prospective observational study on the quality of life of patients attending general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.The data relating to the clinical conditions (disease state, psychological and related to quality of life) of the patients belonging to the above-mentioned clinics will be collected in a specially designed database which will allow us to extract the data in a simple and safe way used for statistical analyses. in clinical research.

Read the detailed description

The Department of Urology has been engaged for years in the field of medical and surgical research relating to benign and oncological pathologies of the prostate, kidney, excretory tract, testicle, as well as urinary continence and dysfunctions of the sexual and reproductive sphere. The accurate acquisition of clinical and psychometric data before and after any treatment, the follow-up analysis, the attention to the patient's global quality of life (QoL) in relation to the particular organic functions affected by the disease, are at the basis of all the medical advances that can be achieved to guarantee ever better care of the individual's health. In the context of urological clinical practice, outpatient activity plays a fundamental role. This activity, which ranges from general urology to sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology, allows us to come into contact with a large number of patients suffering from the most common uropathologies -andrological .

Numerous studies have demonstrated how the treatment and outpatient management of such patients significantly impacts not only the underlying pathology but also their quality of life.

The outpatient management of the urological patient ranges from the recognition of the basic pathology to the diagnosis through the request for clinical-laboratory-instrumental investigations, to the possible indication for a medical or surgical treatment and to the follow-up of the patient.

The main objectives of this data archive are:

  1. Collect clinical, instrumental, laboratory, psychometric and sociodemographic data in patients suffering from a uro-andrological pathology who require a consultation in one of the clinics mentioned above.
  2. Collect data on the natural history of the pathologies in question and on the patients' quality of life in order to analyze the predictive factors of persistence and recurrence of symptoms, improvement or worsening of the clinical picture, and possible progression of the disease (both in benign and malignant form) and improve the care and treatment of the patients under examination.
  3. Having a follow-up and related studies with a number and above all an extension over time that, to date, is not present in the literature or in any scientific production.
03

Conditions studied

  • Urologic Diseases
  • Male Infertility
  • Sexual Medicine

Keywords

  • Male Infertility
  • urology
  • rare male cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The patient population of interest is characterised by: patients who came for outpatient visits to the general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects belonging to general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.
  • subjects >= 18 years old
  • signature of

Exclusion criteria

Exclusion Criteria:

    • subjects \< 18 years
  • presence of mental or physical disability that may prevent the patient from answering the questionnaires.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Uro-andrologic patients

    Subjects belonging to general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.

    Other: Observation during time

Interventions

  • OtherObservation during time

    Evaluation through clinical investigation and questionnaires useful for evaluating the patient's psycho-physical conditions

06

What researchers measure

Primary outcomes

  1. Sexual function - Erectile Function

    Sexual function investigated through: "International Index of Erectile Function" questionnaire IIEF (scoring: 1 - 30 - 6-10: severe; 11-16: Moderate; 17-25: mild; 26-30: absence);

    Time frame: Baseline and up to 6 months

  2. Sexual function - premature ejaculation

    Premature ejaculation investigated through PEDT questionnaire (; Scoring: 0 - 20. \<=8 absence; 9-10 probable; \>=11 premature ejaculation);

    Time frame: Baseline and up to 6 months

  3. Sexual function - male sexual health

    Male sexual health investigated through MSHQ questionnaire (25-item, range: 7 - 80, greater score indicating better function and through Androtest (1 - 32; \> 8 = out of the norm);

    Time frame: Baseline and up to 6 months

  4. Sexual function - androgen deficiency

    Androgen deficiency in elderly males investigated through ADAM questionnaire (range 10 - 50, 10 = absence and 50 = maximal,

    Time frame: Baseline and up to 6 months

  5. Sexual function - satisfaction with treatment of erection problems

    satisfaction with treatment of erection problems investigated through EDITS questionnaire (range = 0-100; higher scores =more treatment satisfaction),

    Time frame: Baseline and up to 6 months

  6. Female sexual function

    Female sexual function investigated through "Female Sexual Function Index" questionnaire - FSFI (range 2 - 36, lower scores = worse sexual functioning),;

    Time frame: Baseline and up to 6 months

  7. Sexual function - sexual distress

    Sexual distress investigated through "Sexual Distress Scale" questionnaire - SDS (range 12- 48, sexual distress = \> 15).

    Time frame: Baseline and up to 6 months

Secondary outcomes

  1. Prostate function - Prostatic Symptoms

    Prostatic Symptoms investigated through IPSS questionnaire "International Prostatic Symptoms Score": , Scoring 0 -7, 0-7 mild symptoms, 8-19 moderate symptoms, 20-35 severe symptoms

    Time frame: Baseline and up to 6 months

  2. Psychological state

    Psychological state investigated through Beck Beck Depression Inventory: Range score 1 - 63; 1-10: normal; 11-16: Mild mood disturbance; 17-20: Borderline clinical depression; 21-30: Moderate depression; 31-40: Severe depression; over 40: Extreme depression.

    Time frame: Baseline and up to 6 months

  3. Prostate function - Incontinence Questionnaire

    Incontinence Questionnaire investigated through ICIQ-SF questionnaire (maximum score of 21; the higher the score, the more severe is the UI, but there is no normal score)

    Time frame: Baseline and up to 6 months

  4. Overactive Bladder

    Overactive Bladder investigated through OAB-q - Overactive Bladder Questionnaire: the score for each of OAB-q domain are summed and transformed to a score ranging from zero to 100. Higher scores indicate more severe symptoms or better quality of life.

    Time frame: Baseline and up to 6 months

  5. Prostate function

    Prostate function investigated through National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) questionnaire: total score range from 0 to 43, three subscales addressing pain (score range 0-21), urinary symptoms (score range 0-10), and quality of life (QOL) (score range 0-12)

    Time frame: Baseline and up to 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2015 (actual). Primary completion is estimated for Feb 2025, 120 months after the start.

Of 36 observational studies under Urologic Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20. This study's planned 120 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2023
First posted
Jan 5, 2024
StartActual
Feb 24, 2015
Primary completionEst.
Feb 2025
CompletionEst.
Jan 31, 2045
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06193850
Lead sponsor
IRCCS San Raffaele
Responsible party
Andrea Salonia (Professor, IRCCS San Raffaele) — Principal investigator
First posted
Jan 5, 2024
Start date
Feb 24, 2015
Primary completion
Feb 2025 (estimated)
Completion
Jan 31, 2045 (estimated)
Last update
Jan 5, 2024

Study contacts

Andrea Salonia, MD
Contact
salonia.andrea@hsr.it
02 2643 5661
Alessia d'Arma, PhD
Contact
darma.alessia@hsr.it
02 2643 5506
Andrea Salonia, MD
principal investigator · IRCCS Ospedale San Raffaele

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion